Outcomes of transcatheter mitral valve repair from the latest nationwide inpatient sample database 2016–2017

Autor:	K K Kurpad, Alexis K. Okoh, S. S. Singh, J Berman, Keith A Hawthorne, Harsh Mehta
Rok vydání:	2020
Předmět:	medicine.medical_specialty business.industry Medicine Sample (statistics) Transcatheter mitral valve repair Cardiology and Cardiovascular Medicine business Surgery
Zdroj:	European Heart Journal. 41
ISSN:	1522-9645 0195-668X
DOI:	10.1093/ehjci/ehaa946.2649
Popis:	Background Transcatheter mitral valve repair (TMVR) is an alternative treatment option for severe mitral regurgitation (severe MR) in patients with high surgical risk. Previous studies have demonstrated safety and efficacy of TMVR. The aim of our study was to assess comorbid and patient outcome data in a nationwide sample. Methods From the Nationwide Inpatient Sample (NIS) 2016–2017, all adult patients with mitral valve regurgitation were identified. Patients were divided into two group- TMVR and SMVR (surgical mitral valve repair). Patients requiring surgical valve replacement were excluded. Primary outcomes were inpatient mortality and length of stay. Multivariate analysis was performed to adjust for comorbidities. Results A total of 6211 TMVR were performed, while 3789 SMVR were performed. TMVR patients were older (78.34 vs 62.26 years) and had more females (48.86 vs 36.18%). Comorbidities were higher in the TMVR group [heart failure (81.02 vs 46.02%, p Conclusion From nationwide data, we report TMVR as a relatively safe treatment modality for severe MR, with comparable inpatient mortality and fewer complications than SMVR, despite having a significantly higher burden of comorbidities. Funding Acknowledgement Type of funding source: None
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::2148435a31c915b1e1eb16382408578a https://doi.org/10.1093/ehjci/ehaa946.2649 Zobrazit plný text záznamu